Differentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI

Combining DCE- with DSC-MRI may enhance diagnostic accuracy in distinguishing progressive disease from pseudoprogression in glioblastoma, particularly during the early post-radiochemotherapy phase when treatment decisions are critical. As the added value of DCE-MRI is limited beyond 12 weeks post-radiochemotherapy, the full protocol is best reserved for early suspicion of progression or unclear cases, while DSC-MRI alone may be sufficient for confirmation imaging after this period.